Does the media prefer INO or MRNA?

In the previous week, Moderna had 84 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 95 mentions for Moderna and 11 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.64 beat Moderna's score of 0.41 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 43 Very Positive mention(s) 9 Positive mention(s) 14 Neutral mention(s) 15 Negative mention(s) 10 Very Negative mention(s) Neutral

Is TARA or INO more profitable?

Protara Therapeutics' return on equity of -41.72% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -41.72% -38.78% Inovio Pharmaceuticals N/A -669.94% -73.97%

Does the media refer more to TARA or INO?

In the previous week, Inovio Pharmaceuticals had 7 more articles in the media than Protara Therapeutics. MarketBeat recorded 11 mentions for Inovio Pharmaceuticals and 4 mentions for Protara Therapeutics. Inovio Pharmaceuticals' average media sentiment score of 0.64 beat Protara Therapeutics' score of -0.19 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Inovio Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is WHWK or INO more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -53.89% -49.97% Inovio Pharmaceuticals N/A -669.94% -73.97%

Does the media refer more to WHWK or INO?

In the previous week, Inovio Pharmaceuticals had 9 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 11 mentions for Inovio Pharmaceuticals and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.67 beat Inovio Pharmaceuticals' score of 0.64 indicating that Whitehawk Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inovio Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INO or GLSI more profitable?

Inovio Pharmaceuticals' return on equity of -669.94% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -669.94% -73.97% Greenwich LifeSciences N/A -793.81% -295.32%

Is CAPR or INO more profitable?

Capricor Therapeutics' return on equity of -56.60% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -56.60% -43.97% Inovio Pharmaceuticals N/A -669.94% -73.97%

Does the media favor CAPR or INO?

In the previous week, Capricor Therapeutics had 60 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 71 mentions for Capricor Therapeutics and 11 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.64 beat Capricor Therapeutics' score of 0.10 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 6 Very Positive mention(s) 9 Positive mention(s) 49 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Inovio Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inovio Pharmaceuticals (INO) Competitors

$1.16 -0.05 (-3.72%)

As of 11:40 AM Eastern

Compare

INO vs. MRNA, TARA, WHWK, GLSI, and CAPR

Should you buy Inovio Pharmaceuticals stock or one of its competitors? Inovio Pharmaceuticals's main competitors and comparable companies include Moderna (MRNA), Protara Therapeutics (TARA), Whitehawk Therapeutics (WHWK), Greenwich LifeSciences (GLSI), and Capricor Therapeutics (CAPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Inovio Pharmaceuticals compare to Moderna?

Inovio Pharmaceuticals (NASDAQ:INO) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Inovio Pharmaceuticals currently has a consensus price target of $3.17, suggesting a potential upside of 174.17%. Moderna has a consensus price target of $66.25, suggesting a potential downside of 55.28%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Inovio Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Moderna had 84 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 95 mentions for Moderna and 11 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.64 beat Moderna's score of 0.41 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	43 Very Positive mention(s)	9 Positive mention(s)	14 Neutral mention(s)	15 Negative mention(s)	10 Very Negative mention(s)	Neutral

Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Moderna	-141.43%	-28.30%	-19.39%

Inovio Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,990.45	-$84.95M	-$0.91	N/A
Moderna	$2.21B	26.76	-$2.82B	-$7.99	N/A

Inovio Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Summary

Inovio Pharmaceuticals beats Moderna on 11 of the 17 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Protara Therapeutics currently has a consensus price target of $26.25, indicating a potential upside of 576.55%. Inovio Pharmaceuticals has a consensus price target of $3.17, indicating a potential upside of 174.17%. Given Protara Therapeutics' higher possible upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Inovio Pharmaceuticals had 7 more articles in the media than Protara Therapeutics. MarketBeat recorded 11 mentions for Inovio Pharmaceuticals and 4 mentions for Protara Therapeutics. Inovio Pharmaceuticals' average media sentiment score of 0.64 beat Protara Therapeutics' score of -0.19 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protara Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Protara Therapeutics has higher earnings, but lower revenue than Inovio Pharmaceuticals. Protara Therapeutics is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
Inovio Pharmaceuticals	$60K	1,990.45	-$84.95M	-$0.91	N/A

Protara Therapeutics' return on equity of -41.72% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Summary

Protara Therapeutics and Inovio Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Inovio Pharmaceuticals had 9 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 11 mentions for Inovio Pharmaceuticals and 2 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.67 beat Inovio Pharmaceuticals' score of 0.64 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inovio Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Whitehawk Therapeutics currently has a consensus price target of $8.20, suggesting a potential upside of 75.21%. Inovio Pharmaceuticals has a consensus price target of $3.17, suggesting a potential upside of 174.17%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Whitehawk Therapeutics' return on equity of -53.89% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-53.89%	-49.97%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Whitehawk Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Whitehawk Therapeutics has higher revenue and earnings than Inovio Pharmaceuticals. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	37.37	-$20.60M	-$1.12	N/A
Inovio Pharmaceuticals	$60K	1,990.45	-$84.95M	-$0.91	N/A

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Whitehawk Therapeutics and Inovio Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Greenwich LifeSciences?

Inovio Pharmaceuticals (NASDAQ:INO) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Inovio Pharmaceuticals' return on equity of -669.94% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Greenwich LifeSciences	N/A	-793.81%	-295.32%

Inovio Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

In the previous week, Inovio Pharmaceuticals had 11 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 11 mentions for Inovio Pharmaceuticals and 0 mentions for Greenwich LifeSciences. Inovio Pharmaceuticals' average media sentiment score of 0.64 beat Greenwich LifeSciences' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Inovio Pharmaceuticals	Positive
Greenwich LifeSciences	Neutral

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Greenwich LifeSciences has lower revenue, but higher earnings than Inovio Pharmaceuticals. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,990.45	-$84.95M	-$0.91	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A

Inovio Pharmaceuticals presently has a consensus price target of $3.17, suggesting a potential upside of 174.17%. Greenwich LifeSciences has a consensus price target of $69.00, suggesting a potential upside of 314.17%. Given Greenwich LifeSciences' higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Inovio Pharmaceuticals beats Greenwich LifeSciences on 12 of the 15 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Inovio Pharmaceuticals has lower revenue, but higher earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	17.02	-$105.04M	-$2.45	N/A
Inovio Pharmaceuticals	$60K	1,990.45	-$84.95M	-$0.91	N/A

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Capricor Therapeutics' return on equity of -56.60% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

In the previous week, Capricor Therapeutics had 60 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 71 mentions for Capricor Therapeutics and 11 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.64 beat Capricor Therapeutics' score of 0.10 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	6 Very Positive mention(s)	9 Positive mention(s)	49 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Capricor Therapeutics currently has a consensus price target of $29.15, indicating a potential upside of 347.09%. Inovio Pharmaceuticals has a consensus price target of $3.17, indicating a potential upside of 174.17%. Given Capricor Therapeutics' higher possible upside, equities research analysts clearly believe Capricor Therapeutics is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Capricor Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Summary

Inovio Pharmaceuticals beats Capricor Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Inovio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INO vs. The Competition

Export

Metric	Inovio Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$119.43M	$4.04B	$7.30B	$12.76B
Dividend Yield	N/A	3.64%	2.54%	10.69%
P/E Ratio	-1.27	11.58	269.82	24.06
Price / Sales	1,990.45	1,291.90	599.79	78.42
Price / Cash	N/A	103.92	78.13	53.57
Price / Book	28.88	18.13	13.45	6.37
Net Income	-$84.95M	-$12.52M	$3.46B	$347.38M
7 Day Performance	5.96%	3.44%	2.08%	-0.23%
1 Month Performance	5.00%	6.91%	4.99%	1.77%
1 Year Performance	-39.53%	60.59%	27.71%	20.27%

Inovio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INO Inovio Pharmaceuticals	3.0781 of 5 stars	$1.16 -4.5%	$3.17 +174.2%	-34.6%	$119.43M	$60K	N/A	320
MRNA Moderna	1.6535 of 5 stars	$59.77 +1.0%	$42.13 -29.5%	+395.8%	$24.01B	$1.94B	N/A	4,700	Trending News Analyst Upgrade Options Volume
TARA Protara Therapeutics	1.6121 of 5 stars	$4.12 +0.0%	$26.25 +537.0%	+28.7%	$231.83M	N/A	N/A	30
WHWK Whitehawk Therapeutics	2.182 of 5 stars	$4.64 -2.6%	$8.20 +76.9%	+192.7%	$229.41M	N/A	N/A	21
GLSI Greenwich LifeSciences	2.1913 of 5 stars	$15.55 +8.3%	$57.00 +266.5%	+28.2%	$228.79M	N/A	N/A	3	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INO) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, TARA, WHWK, GLSI, and CAPR

How does Inovio Pharmaceuticals compare to Moderna?

Summary

How does Inovio Pharmaceuticals compare to Protara Therapeutics?

Summary

How does Inovio Pharmaceuticals compare to Whitehawk Therapeutics?

Summary

How does Inovio Pharmaceuticals compare to Greenwich LifeSciences?

Summary

How does Inovio Pharmaceuticals compare to Capricor Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, TARA, WHWK, GLSI, and CAPR

How does Inovio Pharmaceuticals compare to Moderna?

Do institutionals & insiders have more ownership in INO or MRNA?

Do analysts recommend INO or MRNA?

Does the media prefer INO or MRNA?

Is INO or MRNA more profitable?

Which has higher valuation & earnings, INO or MRNA?

Which has more volatility and risk, INO or MRNA?

Summary

How does Inovio Pharmaceuticals compare to Protara Therapeutics?

Do analysts prefer TARA or INO?

Does the media refer more to TARA or INO?

Which has more risk & volatility, TARA or INO?

Do institutionals and insiders believe in TARA or INO?

Which has higher earnings & valuation, TARA or INO?

Is TARA or INO more profitable?

Summary

How does Inovio Pharmaceuticals compare to Whitehawk Therapeutics?

Does the media refer more to WHWK or INO?

Do analysts rate WHWK or INO?

Is WHWK or INO more profitable?

Which has more risk & volatility, WHWK or INO?

Which has higher earnings & valuation, WHWK or INO?

Do insiders and institutionals have more ownership in WHWK or INO?

Summary

How does Inovio Pharmaceuticals compare to Greenwich LifeSciences?

Is INO or GLSI more profitable?

Which has more volatility and risk, INO or GLSI?

Does the media favor INO or GLSI?

Do insiders and institutionals hold more shares of INO or GLSI?

Which has better valuation & earnings, INO or GLSI?

Do analysts recommend INO or GLSI?

Summary

How does Inovio Pharmaceuticals compare to Capricor Therapeutics?

Which has better earnings & valuation, CAPR or INO?

Do insiders & institutionals have more ownership in CAPR or INO?

Is CAPR or INO more profitable?

Does the media favor CAPR or INO?

Do analysts rate CAPR or INO?

Which has more volatility and risk, CAPR or INO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools